ValuEngine upgraded shares of AstraZeneca (NYSE:AZN) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday.

A number of other research analysts have also commented on the company. JPMorgan Chase & Co. raised AstraZeneca from a neutral rating to an overweight rating in a report on Friday, December 29th. Zacks Investment Research raised AstraZeneca from a sell rating to a hold rating in a report on Wednesday, January 10th. Citigroup raised AstraZeneca to a buy rating in a report on Wednesday, October 18th. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the company a buy rating in a report on Wednesday, November 15th. Finally, Leerink Swann raised their price target on AstraZeneca from $31.00 to $34.00 and gave the company a market perform rating in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $34.48.

Shares of AstraZeneca (AZN) traded up $0.76 during midday trading on Friday, reaching $35.90. The company’s stock had a trading volume of 7,480,000 shares, compared to its average volume of 3,510,000. AstraZeneca has a 1 year low of $27.55 and a 1 year high of $36.70. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The firm has a market capitalization of $90,040.00, a price-to-earnings ratio of 25.64, a PEG ratio of 2.78 and a beta of 0.74.

AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same period last year, the company earned $1.21 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. equities research analysts predict that AstraZeneca will post 1.71 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in AZN. WFG Advisors LP grew its holdings in AstraZeneca by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after acquiring an additional 984 shares during the period. Valeo Financial Advisors LLC acquired a new position in AstraZeneca during the third quarter worth about $133,000. Quadrant Capital Group LLC grew its holdings in AstraZeneca by 18.4% during the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after acquiring an additional 846 shares during the period. Wealthcare Advisory Partners LLC acquired a new position in AstraZeneca during the third quarter worth about $184,000. Finally, FTB Advisors Inc. grew its holdings in AstraZeneca by 3.2% during the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after acquiring an additional 200 shares during the period. 14.73% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/04/astrazeneca-azn-rating-increased-to-strong-buy-at-valuengine.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.